Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa

Kristen N. Schurek, Alexandra K. Marr, Patrick K. Taylor, Irith Wiegand, Lucie Semenec, Bhavjinder K. Khaira, Robert E W Hancock

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Pseudomonas aeruginosa strains isolated from patients with persistent lung infections and cystic fibrosis have been found to gradually develop aminoglycoside resistance over time. The aim of this study was to identify potential contributors to low-level aminoglycoside resistance, which may cause such graduated increases in resistance. The Harvard P. aeruginosa PA14 nonredundant library, consisting of approximately 5,800 mutants, was screened for twofold or greater increases in tobramycin resistance. Mutants carrying mutations in a total of 135 unique genes were identified and confirmed to have reduced susceptibility to tobramycin. Many of these genes were involved predominantly in energy metabolism; however, most of these mutants did not exhibit growth defects under the conditions tested, although some exhibited the small-colony phenotype and/or defects in growth under anaerobic conditions. Lipopolysaccharide mutants were also identified, and it was found that tobramycin had a reduced ability to permeabilize the outer membranes of these mutants. The results of this study emphasize the complexity of the interactions that tobramycin may have within the bacterial cell and introduce a large number of novel genes which may play a role in tobramycin resistance.

Original languageEnglish
Pages (from-to)4213-4219
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume52
Issue number12
DOIs
Publication statusPublished - Dec 2008
Externally publishedYes

Fingerprint

Tobramycin
Aminoglycosides
Pseudomonas aeruginosa
Genes
Growth
Cystic Fibrosis
Energy Metabolism
Libraries
Lipopolysaccharides
Phenotype
Lung
Mutation
Membranes
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Schurek, K. N., Marr, A. K., Taylor, P. K., Wiegand, I., Semenec, L., Khaira, B. K., & Hancock, R. E. W. (2008). Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 52(12), 4213-4219. https://doi.org/10.1128/AAC.00507-08

Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa. / Schurek, Kristen N.; Marr, Alexandra K.; Taylor, Patrick K.; Wiegand, Irith; Semenec, Lucie; Khaira, Bhavjinder K.; Hancock, Robert E W.

In: Antimicrobial Agents and Chemotherapy, Vol. 52, No. 12, 12.2008, p. 4213-4219.

Research output: Contribution to journalArticle

Schurek, KN, Marr, AK, Taylor, PK, Wiegand, I, Semenec, L, Khaira, BK & Hancock, REW 2008, 'Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa', Antimicrobial Agents and Chemotherapy, vol. 52, no. 12, pp. 4213-4219. https://doi.org/10.1128/AAC.00507-08
Schurek, Kristen N. ; Marr, Alexandra K. ; Taylor, Patrick K. ; Wiegand, Irith ; Semenec, Lucie ; Khaira, Bhavjinder K. ; Hancock, Robert E W. / Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa. In: Antimicrobial Agents and Chemotherapy. 2008 ; Vol. 52, No. 12. pp. 4213-4219.
@article{0800e3d3752d4b2d845c2b18e4e048ef,
title = "Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa",
abstract = "Pseudomonas aeruginosa strains isolated from patients with persistent lung infections and cystic fibrosis have been found to gradually develop aminoglycoside resistance over time. The aim of this study was to identify potential contributors to low-level aminoglycoside resistance, which may cause such graduated increases in resistance. The Harvard P. aeruginosa PA14 nonredundant library, consisting of approximately 5,800 mutants, was screened for twofold or greater increases in tobramycin resistance. Mutants carrying mutations in a total of 135 unique genes were identified and confirmed to have reduced susceptibility to tobramycin. Many of these genes were involved predominantly in energy metabolism; however, most of these mutants did not exhibit growth defects under the conditions tested, although some exhibited the small-colony phenotype and/or defects in growth under anaerobic conditions. Lipopolysaccharide mutants were also identified, and it was found that tobramycin had a reduced ability to permeabilize the outer membranes of these mutants. The results of this study emphasize the complexity of the interactions that tobramycin may have within the bacterial cell and introduce a large number of novel genes which may play a role in tobramycin resistance.",
author = "Schurek, {Kristen N.} and Marr, {Alexandra K.} and Taylor, {Patrick K.} and Irith Wiegand and Lucie Semenec and Khaira, {Bhavjinder K.} and Hancock, {Robert E W}",
year = "2008",
month = "12",
doi = "10.1128/AAC.00507-08",
language = "English",
volume = "52",
pages = "4213--4219",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa

AU - Schurek, Kristen N.

AU - Marr, Alexandra K.

AU - Taylor, Patrick K.

AU - Wiegand, Irith

AU - Semenec, Lucie

AU - Khaira, Bhavjinder K.

AU - Hancock, Robert E W

PY - 2008/12

Y1 - 2008/12

N2 - Pseudomonas aeruginosa strains isolated from patients with persistent lung infections and cystic fibrosis have been found to gradually develop aminoglycoside resistance over time. The aim of this study was to identify potential contributors to low-level aminoglycoside resistance, which may cause such graduated increases in resistance. The Harvard P. aeruginosa PA14 nonredundant library, consisting of approximately 5,800 mutants, was screened for twofold or greater increases in tobramycin resistance. Mutants carrying mutations in a total of 135 unique genes were identified and confirmed to have reduced susceptibility to tobramycin. Many of these genes were involved predominantly in energy metabolism; however, most of these mutants did not exhibit growth defects under the conditions tested, although some exhibited the small-colony phenotype and/or defects in growth under anaerobic conditions. Lipopolysaccharide mutants were also identified, and it was found that tobramycin had a reduced ability to permeabilize the outer membranes of these mutants. The results of this study emphasize the complexity of the interactions that tobramycin may have within the bacterial cell and introduce a large number of novel genes which may play a role in tobramycin resistance.

AB - Pseudomonas aeruginosa strains isolated from patients with persistent lung infections and cystic fibrosis have been found to gradually develop aminoglycoside resistance over time. The aim of this study was to identify potential contributors to low-level aminoglycoside resistance, which may cause such graduated increases in resistance. The Harvard P. aeruginosa PA14 nonredundant library, consisting of approximately 5,800 mutants, was screened for twofold or greater increases in tobramycin resistance. Mutants carrying mutations in a total of 135 unique genes were identified and confirmed to have reduced susceptibility to tobramycin. Many of these genes were involved predominantly in energy metabolism; however, most of these mutants did not exhibit growth defects under the conditions tested, although some exhibited the small-colony phenotype and/or defects in growth under anaerobic conditions. Lipopolysaccharide mutants were also identified, and it was found that tobramycin had a reduced ability to permeabilize the outer membranes of these mutants. The results of this study emphasize the complexity of the interactions that tobramycin may have within the bacterial cell and introduce a large number of novel genes which may play a role in tobramycin resistance.

UR - http://www.scopus.com/inward/record.url?scp=57049100540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049100540&partnerID=8YFLogxK

U2 - 10.1128/AAC.00507-08

DO - 10.1128/AAC.00507-08

M3 - Article

VL - 52

SP - 4213

EP - 4219

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -